Navigation Links
Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study

th migraine. An innovative, two-stage, adaptive dose-ranging design formulated through computer simulation was used to facilitate optimal dose selection.

A total of 420 adult patients who experienced migraine attacks, as defined by the International Headache Society criteria, were randomized (330 took drug) to treat a moderate or severe migraine attack with MK-0974 given orally at doses of 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, or 600 mg, or rizatriptan 10 mg, or placebo. Patients enrolled were primarily female (89 percent) with an average age of 41 years. Most treated headaches were moderate in baseline severity and did not have aura.

The first stage of the study evaluated all doses of MK-0974 with rizatriptan and placebo. When a preset number of migraine attacks were treated, an interim efficacy analysis was conducted resulting in dropping the four lowest doses of MK-0974 based on a pre-specified algorithm. The second stage of the study continued with randomization of patients to MK-0974 300 mg, 400 mg or 600 mg or to rizatriptan 10 mg or placebo.

Overall treatment effect was analyzed by comparing the average response of the MK-0974 treatment groups (300 mg, 400 mg and 600 mg) to the response observed in the placebo group. The study was not powered to detect differences between the individual doses of MK-0974 or between MK-0974 doses and rizatriptan.

Study results

For the primary endpoint, the overall treatment effect of MK-0974 in relieving migraine pain (reduction from severe or moderate to mild or none) two hours after dosing was significant compared to placebo (p=0.015). The proportion of patients reporting pain relief at two hours for those treated with MK-0974 was 68.1 percent (300 mg; n=38), 48.2 percent (400 mg; n=45) and 67.5 percent (600 mg, n=40); and 69.5 percent for rizatriptan (n=34) compared to 46.3 percent for placebo (n=115).

A similar pattern was observed for secondary measures in which the overall
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
(Date:5/4/2015)... HOUSTON , TX and VANCOUVER , May ... "Company") (TSX-V: EPI) announced today that it has received notification ... in the US that the Company,s IND application, filed March ... by the FDA of additional chemistry and pharmaceutical data related ... and a Certificate of Analysis on drug product. ...
(Date:5/4/2015)... NEW HAVEN, Conn. , May 4, 2015 ... been chosen by the American Optometric Association (AOA) ... care delivery and outcomes for the millions of ... Measures and Outcomes Registry for Eyecare ... and will securely facilitate efficient secondary uses of ...
(Date:5/1/2015)... 2015   Intarcia Therapeutics, Inc. today announced ... Vice President, Human Resources, reporting directly to Kurt ... new key member of the senior leadership team, Mr. ... Team to assure the Company advances its business, brings ... core values and its dynamic culture. Another essential goal ...
Breaking Medicine Technology:ESSA Pharma Inc. Receives FDA Response on IND Application 2ESSA Pharma Inc. Receives FDA Response on IND Application 3ESSA Pharma Inc. Receives FDA Response on IND Application 4American Optometric Association, Prometheus Research to Create Transformative Health Outcomes Registry 2Intarcia Appoints James P. Brady Vice President, Human Resources 2Intarcia Appoints James P. Brady Vice President, Human Resources 3Intarcia Appoints James P. Brady Vice President, Human Resources 4
... 1, 2010 Flextronics (Nasdaq: FLEX ... a dedicated, 180,000 square foot facility in Senai, ... rise in demand from medical OEMs, while providing ... needs.  Flextronics Medical,s new clean room manufacturing, ISO13485 ...
... ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) { first_result ...
Cached Medicine Technology:Flextronics Medical to Open Malaysia Facility to Complement Existing Low-Cost Footprint and Support Growth for Manufacturing Services 2Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 2Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 3Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 4Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 5Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 6Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 7Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 8Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 9Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 10Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 11Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 12Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 13Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C 14
(Date:5/4/2015)... Sylvia Hawthorn-Deppen shared her experiences living ... remind others in similar situations that they were not alone, ... and Discovery of New Energy” (published by Balboa Press). This ... a renewed press campaign. , “I have spent nearly 60 ... Hawthorn-Deppen says. “As an adolescent I got into trouble with ...
(Date:5/4/2015)... 04, 2015 Fast on the heels ... Trace Amounts, and Allison Folmar, JD, join over 150 ... internationally. , On Sunday, May 24, the conference presents ... possible?" Are you interested in Ryan Hinds' recovery story? ... our war against autism was written by Marcia ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Sara Soulati, ... physician practice management firm in Los Angeles associated with ... the patent-pending status of The Sara Soulati Health For ... in 2010, is a lifestyle modification and disease prevention ... 2015 to the U. S. Patents and Trademarks Office ...
(Date:5/3/2015)... CA (PRWEB) May 03, 2015 Leading ... (CFHI), announced it will be awarding the 2015 Harris ... Knight and Selemawit Ghebrendrias, are the deserving recipients of ... for global service, Harris Llewellyn Wofford. The two recipients ... and passion for global health. , CFHI is ...
(Date:5/3/2015)... San Mateo, CA (PRWEB) May 03, 2015 ... newest service, MnemeTherapy® at two upcoming area seminars. The ... during the PSA Annual Regional Stroke Conference to be ... will be offered on Wednesday, May 13 during the ... Crowne Plaza. , “These seminars offer an excellent ...
Breaking Medicine News(10 mins):Health News:Author launches new press campaign for 2012 book ‘Wheel’ 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 2Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 3Health News:Perhaps the most important information families touched by autism will ever hear is available this month at international conference in Chicago 4Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2
... damage if used improperly , TUESDAY, June 30 (HealthDay ... that the maximum dose for Tylenol and other pain ... , The advisers recommended lowering the maximum dose of ... and other medications. , Part of the problem, according ...
... pandemic since April study , , FLEMINGTON, N.J., June ... that more than one-third of physicians (37%) reported that there ... could result in a catastrophic pandemic, the highest level since ... there was "somewhat of a risk" for a pandemic. , ...
... Foods , LLC announced today that it is voluntarily recalling ... its stores between May 9th and May 15th. This ... by the JBS Swift Beef Company, which yesterday voluntarily expanded ... be contaminated with E. coli 0157:H7 to approximately 380,000 pounds ...
... can lead to serious injury , , , ... thrill of skateboarding. They learn to master their skills of ... American College of Foot and Ankle Surgeons (ACFAS), such tricks, ... and ankle injuries. , , Foot and ankle ...
... [Brown University] A front portion of the brain that ... according to new Brown University research. This section of ... different pronunciations of the same speech sound (such as a ... have solved a mystery. "No two pronunciations of the ...
... , NEW YORK, June 30 A new report on ... singles out Hospital for Special Surgery as the only hospital ... surgical site infection (SSI) compared to the state average for ... as a best practice," said Thomas P. Sculco, M.D., surgeon-in-chief ...
Cached Medicine News:Health News:FDA Advisers Recommend Smaller Doses of Acetaminophen 2Health News:More than One-Third of Docs Say Risk Level Rising for Potential H1N1 Flu Pandemic 2Health News:More than One-Third of Docs Say Risk Level Rising for Potential H1N1 Flu Pandemic 3Health News:WinCo Foods Voluntarily Recalls Beef and Ground Beef Sold at Some Stores Between May 9 and May 15, 2009 Due to Possible Contamination 2Health News:Surgeons Warn: Skateboarding Tough on Feet, Ankles 2Health News:Brain section multitasks, handling phonetics and decision-making 2Health News:Hospital for Special Surgery is Only New York Hospital with Significantly Lower Surgical Site Infection Rate for Hip Replacement Compared to State Average 2
... The next generation Powerheart AED has ... our flagship, feature-rich AED offering. The ... new customer-friendly features such as more ... new lighter weight, redesigned form factor, ...
... Plus™ is the best EMR value for ... in mind, Charting Plus™ relies heavily on ... features to improve documentation quality and increase ... content is specific to your medical specialty. ...
... the vast information needs of orthopedics specialty. ... for common orthopedics complaints, history of present ... also includes orthopedics specific ICD and CPT ... charges and quickly generate electronic Superbill at ...
... Maximo, Model 7303, incorporates new advances in CRT ... Proven Marquis ICD Platform. With this device, ... in 9 seconds or less throughout the life ... (14% increase in longevity over InSync II Marquis) ...
Medicine Products: